AXGN
$30.78-0.38 (-1.22%)
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerv...
Recent News
Is Axogen (AXGN) Fairly Priced After Strong 72.7% One Year Share Gain
Wondering if Axogen at around US$31.16 is offering fair value, or if you might be paying too much for recent excitement in the share price. The stock has been choppy in the short term, with a 1.9% decline over the last week and a 10.0% decline over the last month, yet it still sits on a small 0.5% gain year to date and a strong 72.7% return over the last year. These moves come against a backdrop of Axogen continuing to attract attention as a specialized medical equipment name, with investors...
Do Options Traders Know Something About Axogen Stock We Don't?
Investors need to pay close attention to AXGN stock based on the movements in the options market lately.
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen (NASDAQ:AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company’s ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected a
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+
AxoGen (NASDAQ:AXGN) executives outlined a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application (BLA) approval for AVANCE during a recent investor discussion. Business momentum and commercial perf
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
AxoGen (NASDAQ:AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected standard of care, while also providing updates on growth expectations, reimbursement progress, and the im